Curbside Consult with Dr. Jayne 5/18/26 – Image for illustrative purposes only (Image credits: Unsplash)
Healthcare leaders are weighing a provocative question this week. Should autonomous artificial intelligence tools that guide patient care receive the same licensing scrutiny as human clinicians, or should they fall under existing medical device rules? The discussion gained traction after a recent reader poll highlighted deep divisions on oversight for these emerging systems.
Poll Sparks Fresh Scrutiny
A simple survey asked whether autonomous health AI should operate under clinician-style licensing or device-style regulation. Responses revealed no easy consensus. Many participants described the technology as promising yet immature, likening it to a powerful tool that still requires careful handling. The poll also touched on practical use. Readers considered whether they would trust such a system for their own health needs. Feedback ranged from outright skepticism to cautious interest in limited applications. Several noted that real-world performance data remains thin, especially for complex cases involving multiple conditions or emotional factors.
Licensing Path Brings Its Own Hurdles
Treating AI like a clinician would mean navigating a patchwork of state rules. Physicians already face varying requirements for education, exams, and ongoing education across jurisdictions. Adding AI to this framework would demand new definitions for scope of practice and accountability. Proponents argue the approach could create clearer standards and encourage responsible development. Critics point out the administrative burden. An AI system might need approvals in every state where it serves patients, creating delays that slow innovation without guaranteeing safety.
Device Regulation Offers Familiar Ground
The alternative treats AI as software as a medical device. This route aligns with how the FDA currently reviews many digital health tools. Updates to algorithms would still require review, however, raising concerns about constant re-submissions for every improvement. Stakeholders worry this model struggles with rapidly evolving systems. A static implant or medication fits neatly into device categories, but adaptive AI does not. Frequent changes could overwhelm regulators and slow deployment in areas that need it most.
Human Element Remains Central
Even with strong oversight, experts stress that unsupervised AI is not ready for broad use. Complex patient visits often involve subtle cues and personal context that algorithms still miss. Pilots in low-stakes settings, such as routine executive screenings, may offer a safer starting point. The conversation continues to evolve as more data emerges. Regulators, clinicians, and developers will need to balance innovation with patient protection in the months ahead.
